Literature DB >> 30002124

Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD.

Diego Villa1, Laurie H Sehn2, Christina Aquino-Parsons3, Petter Tonseth4, David W Scott2, Alina S Gerrie2, Donald Wilson4, François Bénard4, Randy D Gascoyne5, Graham W Slack5, Pedro Farinha5, James Morris3, Tom Pickles3, Joseph M Connors2, Kerry J Savage2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30002124      PMCID： PMC6269305          DOI： 10.3324/haematol.2018.196782

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.

Authors:  Ralph M Meyer; Mary K Gospodarowicz; Joseph M Connors; Robert G Pearcey; Woodrow A Wells; Jane N Winter; Sandra J Horning; A Rashid Dar; Chaim Shustik; Douglas A Stewart; Michael Crump; Marina S Djurfeldt; Bingshu E Chen; Lois E Shepherd
Journal:  N Engl J Med       Date:  2011-12-11       Impact factor: 91.245

2.  Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

Authors:  Michael Schaapveld; Berthe M P Aleman; Anna M van Eggermond; Cécile P M Janus; Augustinus D G Krol; Richard W M van der Maazen; Judith Roesink; John M M Raemaekers; Jan Paul de Boer; Josée M Zijlstra; Gustaaf W van Imhoff; Eefke J Petersen; Philip M P Poortmans; Max Beijert; Marnix L Lybeert; Ina Mulder; Otto Visser; Marieke W J Louwman; Inge M Krul; Pieternella J Lugtenburg; Flora E van Leeuwen
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

3.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

4.  Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.

Authors:  Marc P E André; Théodore Girinsky; Massimo Federico; Oumédaly Reman; Catherine Fortpied; Manuel Gotti; Olivier Casasnovas; Pauline Brice; Richard van der Maazen; Alessandro Re; Véronique Edeline; Christophe Fermé; Gustaaf van Imhoff; Francesco Merli; Réda Bouabdallah; Catherine Sebban; Lena Specht; Aspasia Stamatoullas; Richard Delarue; Valeria Fiaccadori; Monica Bellei; Tiana Raveloarivahy; Annibale Versari; Martin Hutchings; Michel Meignan; John Raemaekers
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

5.  Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.

Authors:  Stephanie Sasse; Paul J Bröckelmann; Helen Goergen; Annette Plütschow; Horst Müller; Stefanie Kreissl; Carolin Buerkle; Sven Borchmann; Michael Fuchs; Peter Borchmann; Volker Diehl; Andreas Engert
Journal:  J Clin Oncol       Date:  2017-04-18       Impact factor: 44.544

6.  Factors affecting late mortality from heart disease after treatment of Hodgkin's disease.

Authors:  S L Hancock; M A Tucker; R T Hoppe
Journal:  JAMA       Date:  1993-10-27       Impact factor: 56.272

7.  Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.

Authors:  Belinda A Campbell; Nick Voss; Tom Pickles; James Morris; Randy D Gascoyne; Kerry J Savage; Joseph M Connors
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

8.  MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease.

Authors:  P Klimo; J M Connors
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

9.  CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

Authors:  David J Straus; Sin-Ho Jung; Brandelyn Pitcher; Lale Kostakoglu; John C Grecula; Eric D Hsi; Heiko Schöder; Leslie L Popplewell; Julie E Chang; Craig H Moskowitz; Nina Wagner-Johnston; John P Leonard; Jonathan W Friedberg; Brad S Kahl; Bruce D Cheson; Nancy L Bartlett
Journal:  Blood       Date:  2018-07-26       Impact factor: 22.113

10.  Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

Authors:  John Radford; Tim Illidge; Nicholas Counsell; Barry Hancock; Ruth Pettengell; Peter Johnson; Jennie Wimperis; Dominic Culligan; Bilyana Popova; Paul Smith; Andrew McMillan; Alison Brownell; Anton Kruger; Andrew Lister; Peter Hoskin; Michael O'Doherty; Sally Barrington
Journal:  N Engl J Med       Date:  2015-04-23       Impact factor: 91.245
View more
  6 in total

Review 1.  Hodgkin lymphoma.

Authors:  Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett
Journal:  Nat Rev Dis Primers       Date:  2020-07-23       Impact factor: 52.329

2.  Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach.

Authors:  Phoebe T M Cheng; Diego Villa; R Petter Tonseth; David W Scott; Alina S Gerrie; Ciara L Freeman; Tom Pickles; Andrea C Lo; Pedro Farinha; Jeffrey W Craig; Graham W Slack; Randy D Gascoyne; François Bénard; Don Wilson; Brian Skinnider; Joseph M Connors; Laurie H Sehn; Kerry J Savage
Journal:  Blood Adv       Date:  2021-09-28

3.  Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

Authors:  Angela Aldin; Lisa Umlauff; Lise J Estcourt; Gary Collins; Karel Gm Moons; Andreas Engert; Carsten Kobe; Bastian von Tresckow; Madhuri Haque; Farid Foroutan; Nina Kreuzberger; Marialena Trivella; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2019-09-16

4.  Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

Authors:  Angela Aldin; Lisa Umlauff; Lise J Estcourt; Gary Collins; Karel Gm Moons; Andreas Engert; Carsten Kobe; Bastian von Tresckow; Madhuri Haque; Farid Foroutan; Nina Kreuzberger; Marialena Trivella; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-01-13

5.  Pegfilgrastim in Supportive Care of Hodgkin Lymphoma.

Authors:  Claudio Cerchione; Davide Nappi; Alessandra Romano; Giovanni Martinelli
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

Review 6.  Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.

Authors:  Theodoros P Vassilakopoulos; John V Asimakopoulos; Kostas Konstantopoulos; Maria K Angelopoulou
Journal:  Ther Adv Hematol       Date:  2020-02-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.